Accuray Inc (NASDAQ:ARAY) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems. Accuray Inc has a market cap of $229.750 million; its shares were traded at around $2.61 with and P/S ratio of 0.56.
For the last quarter Accuray Inc reported a revenue of $117.4 million, compared with the revenue of $113.8 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $418.8 million, an increase of 3.4% from last year. For the complete 30-year financial data, please go here. . For the last five years Accuray Inc had an average revenue growth rate of 2.3% a year.
The reported loss per diluted share was 19 cents for the year, compared with the loss per share of $0.51 in the previous year. The Accuray Inc had an operating margin of 0.14%, compared with the operating margin of -0.94% a year before. The 10-year historical median operating margin of Accuray Inc is -3.74%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Accuray Inc has the cash and cash equivalents of $76.8 million, compared with $83.1 million in the previous year. The long term debt was $159.8 million, compared with $131.1 million in the previous year. Accuray Inc has a financial strength rank of 4 (out of 10).
At the current stock price of $2.61, Accuray Inc is traded at 57.4% discount to its historical median P/S valuation band of $6.12 . The P/S ratio of the stock is 0.56, while the historical median P/S ratio is 1.28. The stock lost 33.17% during the past 12 months.
For the complete 20-year historical financial data of ARAY, click here.
This article first appeared on